Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Approved Rx

14

US Previously Marketed

1

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Cyclooxygenase-2

1

Dihydroorotate dehydrogenase

1

Dihydroorotate dehydrogenase (quinone), mitochondrial

1

Tyrosine-protein kinase JAK1

1

Tyrosine-protein kinase JAK2

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

4

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1997

1

1998

3

2001

2

2002

1

2005

1

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Rheumatoid arthritis

2

Active rheumatoid arthritis

1

Hyperuricemia in patients with gout

1

Multiple sclerosis

1

Osteoarthritis

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

3

Palliative

2

Secondary

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Penetrant

2

CNS Non-penetrant

1

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Genzyme

1

Pfizer

1

Pfizer|National Institutes of Health

1

Teijin Pharma

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Protein

11

Chemical

4

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

15

ChEMBL

15

DRUG BANK

15

EMA ASSESSMENT REPORTS

15

EVMPD

15

All Match

Any Match

Exclude Selected

Exclude Selected

Protein Type

MONOCLONAL ANTIBODY

7

CYTOKINE

1

ENZYME

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

11

MUSCULO-SKELETAL SYSTEM

3

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

IMMUNOSUPPRESSANTS

10

ANTIGOUT PREPARATIONS

2

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

1

ANTINEOPLASTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

IMMUNOSUPPRESSANTS

10

ANTIGOUT PREPARATIONS

2

ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

1

OTHER ANTINEOPLASTIC AGENTS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Tumor necrosis factor alpha (TNF-a) inhibitors

5

Interleukin inhibitors

3

Selective immunosuppressants

2

Coxibs

1

Monoclonal antibodies

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

12

Salts, Hydrates, Esters, etc.

3

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for "EMA EPAR|DISEASES|MUSCULOSKELETAL DISEASES|RHEUMATIC DISEASES" in comments (approximate match)

Showing 1 - 10 of 15 results

First page disabled
Previous page disabled
1
Next page
Next page

Febuxostat

101V0R1N2E

Export Data
Search for Structure

Status:

US Approved Rx (2023)

First approved in 2009

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Xanthine dehydrogenase

Conditions:

Hyperuricemia in patients with gout

Febuxostat (ULORIC) is a novel, xanthine oxidase/dehydrogenase (XO/XDH) inhibitor being developed by Teijin, TAP Pharmaceuticals, and Ipsen for the treatment of gout. The currently available XO inhibitor, allopurinol, has been associated with serious...

instances of severe hypersensitivity, in some cases leading to fatalities. There is some suggestion that febuxostat is less prone to excacerbate systemic inflammatory events in animal studies. Febuxostat, a xanthine oxidase inhibitor, achieves its therapeutic effect by decreasing serum uric acid. Febuxostat is not expected to inhibit other enzymes involved in purine and pyrimidine synthesis and metabolism at therapeutic concentrations. Febuxostat is used for the treatment of hyperuricemia in patients with gout.

PEGLOTICASE

R581OT55EA

Subunit 1 (298) Similarity Search Subunit 2 (298) Similarity Search Subunit 3 (298) Similarity Search Subunit 4 (298) Similarity Search

Export Data
Sequence Search

Subunit 1 (298) Similarity Search Subunit 2 (298) Similarity Search Subunit 3 (298) Similarity Search Subunit 4 (298) Similarity Search

Status:

US Approved Rx (2010)

First approved in 2010

Class:

PROTEIN

TOCILIZUMAB

I031V2H011

Subunit 1 (448) Similarity Search Subunit 2 (448) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Export Data
Sequence Search

Subunit 1 (448) Similarity Search Subunit 2 (448) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Status:

US Approved Rx (2013)

First approved in 2010

Class:

PROTEIN

CANAKINUMAB

37CQ2C7X93

Subunit 1 (448) Similarity Search Subunit 2 (448) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Export Data
Sequence Search

Subunit 1 (448) Similarity Search Subunit 2 (448) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Status:

US Approved Rx (2009)

First approved in 2009

Class:

PROTEIN

GOLIMUMAB

91X1KLU43E

Subunit 1 (456) Similarity Search Subunit 2 (456) Similarity Search Subunit 3 (215) Similarity Search Subunit 4 (215) Similarity Search

Export Data
Sequence Search

Subunit 1 (456) Similarity Search Subunit 2 (456) Similarity Search Subunit 3 (215) Similarity Search Subunit 4 (215) Similarity Search

Status:

US Approved Rx (2013)

First approved in 2009

Class:

PROTEIN

CERTOLIZUMAB PEGOL

UMD07X179E

Subunit 1 (229) Similarity Search Subunit 2 (214) Similarity Search

Export Data
Sequence Search

Subunit 1 (229) Similarity Search Subunit 2 (214) Similarity Search

Status:

US Approved Rx (2008)

First approved in 2008

Class:

PROTEIN

ABATACEPT

7D0YB67S97

Subunit 1 (383) Similarity Search Subunit 2 (383) Similarity Search

Export Data
Sequence Search

Subunit 1 (383) Similarity Search Subunit 2 (383) Similarity Search

Status:

US Approved Rx (2005)

First approved in 2005

Class:

PROTEIN

ADALIMUMAB

FYS6T7F842

Subunit 1 (451) Similarity Search Subunit 2 (451) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Export Data
Sequence Search

Subunit 1 (451) Similarity Search Subunit 2 (451) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Status:

US Approved Rx (2021)

First approved in 2002

Class:

PROTEIN

ANAKINRA

9013DUQ28K

Subunit 1 (153) Similarity Search

Export Data
Sequence Search

Subunit 1 (153) Similarity Search

Status:

US Approved Rx (2001)

First approved in 2001

Class:

PROTEIN

INFLIXIMAB

B72HH48FLU

Subunit 1 (450) Similarity Search Subunit 2 (450) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Export Data
Sequence Search

Subunit 1 (450) Similarity Search Subunit 2 (450) Similarity Search Subunit 3 (214) Similarity Search Subunit 4 (214) Similarity Search

Status:

US Approved Rx (2019)

First approved in 1998

Class:

PROTEIN

Showing 1 - 10 of 15 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1